Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-In-Human, Multicenter, Open-Label, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase I, First-In-Human, Multicenter, Open-Label, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary) ; GQ 1007 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Salivary gland cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Suzhou GeneQuantum Healthcare

    • Most Recent Events

    • 06 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top